TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome
A genetic mutation in 10-25% of acute myeloid leukemia patients explains resistance to T-cell therapy and suggests effective drug combinations.
TP53 mutations (present in 10-15% of de novo and 25% of therapy-related AML) create an immunosuppressive secretome that directly impairs T-cell function in response to BiTE therapy via TGF-β1, explaining the modest clinical activity of AMG 330 in an important AML subgroup. This mechanistic insight identifies TGF-β1 pathway inhibition as a rational combination partner for T-cell engagers in TP53-mutant AML.
What the study was
- Study design
- Translational mechanistic study (in vitro + primary AML patient samples)
- Population
- AML patients with TP53 deletion/knockdown; in vitro co-culture models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
High mechanistic novelty — TGF-β1 as mediator of BiTE resistance in TP53-deficient AML — published in Leukemia, a top hematology journal; directly relevant to designing combination immunotherapy trials in AML.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.